Zimmer Biomet Holdings, Inc.’s Stock Price Soars to $104.54, Marking a Robust 2.95% Uptick

Zimmer Biomet Holdings, Inc. (ZBH)

104.54 USD +3.00 (+2.95%) Volume: 2.66M

Zimmer Biomet Holdings, Inc.’s stock price is currently at 104.54 USD, marking a positive shift of +2.95% this trading session with a trading volume of 2.66M. Despite a slight YTD decrease of -1.21%, ZBH continues to be a key player in the medical devices market.

Latest developments on Zimmer Biomet Holdings, Inc.

Today, Zimmer Biomet Holdings Inc. (NYSE:ZBH) experienced a mix of highs and lows in the stock market. Despite facing losses, the company’s stock outperformed competitors, showcasing its resilience in the market. However, Zimmer Biomet Holdings also set a new 12-month low, causing some concern among investors. This fluctuation in stock price may have been influenced by recent sell-offs, such as the 4,885 shares sold by ST Germain D J Co. Inc. and shares sold by Douglas Lane & Associates LLC. Investors will be closely monitoring the company’s performance in the coming days to see how it recovers from this dip.

A look at Zimmer Biomet Holdings, Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, Zimmer Biomet Holdings has a positive long-term outlook. With high scores in value and momentum, the company is positioned well for growth and potential returns for investors. While the resilience score is lower, Zimmer Biomet Holdings’ strong value and momentum scores indicate a promising future for the company.

Zimmer Biomet Holdings, Inc. is a company that designs, develops, manufactures, and markets medical equipment such as orthopedic, dental, and spinal reconstructive implants. With a focus on innovation and serving patients worldwide, Zimmer Biomet Holdings is positioned to continue its growth and success in the medical equipment industry.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma